Acceleron Announces Presentation of New Interim Phase 2 Sotatercept Clinical Data in Beta-Thalassemia

Acceleron Pharma (NASDAQ: XLRN today announced that data in five abstracts for sotatercept and ACE-536, Acceleron's programs to treat red blood cell disorders, will be presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition. The conference will take place on December 7-10th at the Ernest N. Morial Convention Center in New Orleans, Louisiana. Key information to be presented include new interim data from the ongoing phase 2 clinical trial of sotatercept in patients with beta-thalassemia. Initial interim data from the 0.5 mg/kg dose level will be presented in a See full press release
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsGuidanceContractsFDALegalManagementGlobal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!